EBMC-710GO FOR OBESITY
EBMC-710GO, our lead asset, is an oral MC3R/ MC4R dual agonist in clinical development as a next-generation weight-loss treatment
EBMC-710GO is being evaluated in a Phase 1 clinical trial in people with overweight or obesity

Kalohexis addresses shortcomings in the standard-of-care in a market with massive unmet need
Overweight and obese
adults in the US
adults in the US
Annual medical
expenditures
expenditures
of US healthcare
spending
spending
EBMC-710GO represents a pivotal shift in weight-loss treatment
1
Effective Weight Loss
Achieved 11.7% weight loss in 13 weeks in primate models of diet-induced obesity
2
Minimal Weight Regain
Unlike GLP-1s, 710GO showed minimal rebound weight gain after treatment discontinuation in animal studies
3
Lean Mass Sparing
Preferential reduction in fat mass and retention of lean mass in obese animal models
4
Complementary Mechanism
Potential for combination with incretin-based therapies